These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25467927)

  • 1. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501.
    Gervais R; Le Caer H; Monnet I; Falchero L; Baize N; Olivero G; Thomas P; Berard H; Auliac JB; Chouaid C;
    Clin Lung Cancer; 2015 Mar; 16(2):100-5. PubMed ID: 25467927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, controlled phase III study of cyclophosphamide, doxorubicin, and vincristine with etoposide (CAV-E) or teniposide (CAV-T), followed by recombinant interferon-alpha maintenance therapy or observation, in small cell lung carcinoma patients with complete responses.
    Tummarello D; Mari D; Graziano F; Isidori P; Cetto G; Pasini F; Santo A; Cellerino R
    Cancer; 1997 Dec; 80(12):2222-9. PubMed ID: 9404698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
    Lebeau B; Chouaïd C; Baud M; Masanès MJ; Febvre M
    Lung Cancer; 2010 Feb; 67(2):188-93. PubMed ID: 19394109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Small cell lung cancer (SCLC): a randomized trial of cyclophosphamide, adriamycin, vincristine plus etoposide (CAV-E) or teniposide (CAV-T) as induction treatment, followed in complete responders by alpha-interferon or no treatment, as maintenance therapy.
    Tummarello D; Graziano F; Mari D; Cetto G; Pasini F; Antonio S; Isidori P; Gasparini S
    Anticancer Res; 1994; 14(5B):2221-7. PubMed ID: 7840527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Randomised phase II study evaluating oral combination chemotherapy (CCNU, cyclophosphamide, etoposide) and intravenous chemotherapy as second-line treatment for relapsed small cell bronchial carcinoma (Trial GFPC0501)].
    Gervais R; Le Guen Y; Le Caer H; Paillotin D; Chouaid C;
    Rev Mal Respir; 2007 May; 24(5):653-8. PubMed ID: 17519820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial of hybrid administration of cyclophosphamide, doxorubicin, and vincristine (CAV)/cisplatin and etoposide (PVP) versus sequential administration of CAV-PVP for the treatment of patients with small cell lung carcinoma: results of long term follow-up.
    Ueoka H; Kiura K; Tabata M; Kamei H; Gemba K; Sakae K; Hiraki Y; Hiraki S; Segawa Y; Harada M
    Cancer; 1998 Jul; 83(2):283-90. PubMed ID: 9669811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
    Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
    Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group.
    Roth BJ; Johnson DH; Einhorn LH; Schacter LP; Cherng NC; Cohen HJ; Crawford J; Randolph JA; Goodlow JL; Broun GO
    J Clin Oncol; 1992 Feb; 10(2):282-91. PubMed ID: 1310103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoposide combined with cyclophosphamide plus vincristine compared with doxorubicin plus cyclophosphamide plus vincristine and with high-dose cyclophosphamide plus vincristine in the treatment of small-cell carcinoma of the lung: a randomized trial of the Bristol Lung Cancer Study Group.
    Hong WK; Nicaise C; Lawson R; Maroun JA; Comis R; Speer J; Luedke D; Hurtubise M; Lanzotti V; Goodlow J
    J Clin Oncol; 1989 Apr; 7(4):450-6. PubMed ID: 2538577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
    Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
    Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy.
    Souhami RL; Spiro SG; Rudd RM; Ruiz de Elvira MC; James LE; Gower NH; Lamont A; Harper PG
    J Natl Cancer Inst; 1997 Apr; 89(8):577-80. PubMed ID: 9106647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: an Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group.
    Murray N; Livingston RB; Shepherd FA; James K; Zee B; Langleben A; Kraut M; Bearden J; Goodwin JW; Grafton C; Turrisi A; Walde D; Croft H; Osoba D; Ottaway J; Gandara D
    J Clin Oncol; 1999 Aug; 17(8):2300-8. PubMed ID: 10561291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline.
    Cheng S; Evans WK; Stys-Norman D; Shepherd FA;
    J Thorac Oncol; 2007 Apr; 2(4):348-54. PubMed ID: 17409809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
    Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
    Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of limited-stage small-cell lung cancer with cyclophosphamide, doxorubicin, and vincristine with or without etoposide: a randomized trial of the North Central Cancer Treatment Group.
    Jett JR; Everson L; Therneau TM; Krook JE; Dalton RJ; Marschke RF; Veeder MH; Brunk SF; Mailliard JA; Twito DI
    J Clin Oncol; 1990 Jan; 8(1):33-8. PubMed ID: 2153193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
    Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
    Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Small cell lung carcinoma: role of thoracic irradiation and its timing in relation to chemotherapy].
    Payne DG; Murray N; Warde P
    Bull Cancer; 1994 Feb; 81(2):119-28. PubMed ID: 7894117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.
    von Pawel J; Schiller JH; Shepherd FA; Fields SZ; Kleisbauer JP; Chrysson NG; Stewart DJ; Clark PI; Palmer MC; Depierre A; Carmichael J; Krebs JB; Ross G; Lane SR; Gralla R
    J Clin Oncol; 1999 Feb; 17(2):658-67. PubMed ID: 10080612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Six vs twelve cycles for complete responders to chemotherapy in small cell lung cancer: definitive results of a randomized clinical trial. The "Petites Cellules" Group.
    Lebeau B; Chastang C; Allard P; Migueres J; Boita F; Fichet D
    Eur Respir J; 1992 Mar; 5(3):286-90. PubMed ID: 1315294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized study comparing cyclophosphamide, doxorubicin, vincristine (CAV) with cyclophosphamide, etoposide, vincristine, methotrexate (CEVM) in patients with small cell lung cancer.
    Erkişi M; Unsal M; Tunali C; Burgut R; Doran F
    J Chemother; 1993 Feb; 5(1):56-9. PubMed ID: 8384659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.